Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion    OXUR   BE0003846632

OXURION (OXUR)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 12/14 05:35:21 pm
3.74 EUR   -0.27%
10/16OXURION NV : quaterly earnings release
09/03THROMBOGENICS NV : half-yearly earnings release
03/12THROMBOGENICS NV : annual earnings release
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
3.575(c) 3.74(c) 3.785(c) 3.75(c) 3.74(c) Last
51 634 44 267 21 334 16 259 39 161 Volume
-4.67% +4.62% +1.20% -0.92% -0.27% Change
More quotes
Financials (EUR)
Sales 2018 3,00 M
EBIT 2018 -30,0 M
Net income 2018 -29,0 M
Finance 2018 24,0 M
Yield 2018 -
Sales 2019 3,00 M
EBIT 2019 -28,0 M
Net income 2019 -28,0 M
Debt 2019 4,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 39,8x
EV / Sales2019 49,2x
Capitalization 144 M
More Financials
Company
Oxurion (formerly ThromboGenics) specializes in the research and development of bio-therapeutic products for treating cardiovascular diseases, ophthalmic disorders, and cancers. Net sales break down by source of income as follows: - sales of products (86.1%); - royalties (13.9%). 
More about the company
Latest news on OXURION
11/07OXURION : licences heparanase blockers from Beta Therapeutics
AQ
11/05OXURION : and Beta Therapeutics To Develop New Heparanase Inhibitors for Treatme..
PU
11/02OXURION : November is Diabetic Eye Disease Awareness Month at Prevent Blindness
PU
10/29OXURION : Announces the Appointment of Adrienne Graves to its Board of Directors
PU
10/25OXURION : to Present at the Upcoming Ophthalmology Innovation Summit and Provide..
AQ
10/24OXURION : to Present at the Upcoming Ophthalmology Innovation Summit and Provide..
PU
10/22OXURION : Extends Partnership with Retina Global in Support of Bolivian Diabetic..
PU
10/19OXURION : Business Update – Q3 2018
PU
10/19OXURION : NV Business Update - Q3 2018
GL
10/19OXURION : 3rd quarter results
CO
More news
Analyst Recommendations on OXURION
More recommendations
Sector news : Biotechnology & Medical Research - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/13Lilly, Incyte Get FDA Fast-Track Designation for Baricitinib in Systemic Lupu..
DJ
12/10Almost half of S&P 500 stocks in a bear market
RE
12/10ROCHE : Gilead Sciences snares Roche veteran O'Day as CEO
RE
12/10LONZA : to Establish Biomanufacturing Base in China
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart OXURION
Duration : Period :
Oxurion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 6,00 €
Spread / Average Target 60%
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
OXURION10.85%163
IQVIA HOLDINGS INC24.11%24 306
CELLTRION, INC.--.--%24 149
LONZA GROUP16.86%23 031
INCYTE CORPORATION-28.95%14 320
SEATTLE GENETICS, INC.14.02%9 843